Skip to content

Effect of EIT-guided PEEP Titration on the Prognosis of Patients with Moderate to Severe ARDS

Effect of EIT-guided PEEP Titration on the Prognosis of Patients with Moderate to Severe ARDS

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05207202
Enrollment
190
Registered
2022-01-26
Start date
2022-02-20
Completion date
2023-07-20
Last updated
2025-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clinical Outcomes

Brief summary

Acute respiratory syndrome distress (ARDS) is a clinical common syndrome with high mortality. Mechanical ventilation (MV) is the cornerstone of management of ARDS but can lead to ventilator-induced lung injury. Positive end-expiratory pressure (PEEP), as one of main component of MV, has been widely used in the clinical practice. However, the PEEP selection is still a difficult problem for moderate to severe ARDS patients. EIT, an imaging tool evaluating the regional ventilation distribution at the bedside, can achieve the individual PEEP selection for all mechanically ventilated patients. This article compared the effect of PEEP titrated guided by EIT with fraction of inspired oxygen (FiO2)-PEEP table on the clinical outcomes.

Detailed description

This is a prospective, multicenter, single-blind, parallel-group, adaptive randomized controlled trial (RCT) with intention-to-treat analysis which aims to determine the effects of PEEP setting guided by EIT on the clinical outcomes for moderate or severe ARDS patients ventilated with lung protective ventilation strategy. Adult patients with moderate to severe ARDS less than 72 hours after diagnosis will be included in this study. Patients in the intervention group will receive PEEP titrated by EIT with a stepwise decrease PEEP trial, whereas patients in the control group will select PEEP based on the FiO2-PEEP table. Other ventilator parameters will be set according to the ARDSnet strategy. The primary outcome is 28-day mortality. The secondary outcomes include ventilator-free days and shock-free days at day 28, length of ICU and hospital stay, the rate of successful weaning, proportion requiring rescue therapies, compilations, respiratory variables, and Sequential Organ Failure Assessment (SOFA). This study will also perform the interim analysis and subgroup analysis.

Interventions

DEVICEelectrical impedance tomography

PEEP titrated by EIT will be performed with a decremental trial at the enrollment. Right after completing RM, PEEP will be set to 20cmH2O and then reduced in steps of 2cmH2O from 20 to zero every 2min.

Sponsors

Southeast University, China
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Age≥18 years 2. Moderate-to-severe ARDS, defined by the ARDS Definition Task Force in the Berlin definition (partial pressure of arterial oxygen \[PaO2\]:FiO2 ratio ≤200 mmHg with a PEEP ≥5 cmH2O) 3. Diagnosis of ARDS less than 72 hours

Exclusion criteria

1. Expected to be mechanically ventilated for less than 48 hours 2. Severe chronic respiratory diseases requiring long-term home oxygen therapy or noninvasive MV 3. Undrained pneumothorax or subcutaneous emphysema 4. Undergoing extracorporeal membrane oxygenation (ECMO) before enrollment 5. Contraindication to the use of EIT (pacemaker, automatic implantable cardioverter defibrillator, and implantable pumps) 6. Severe neuromuscular disease 7. Hemodynamic instability 8. Contraindications to hypercapnia, such as intracranial hypertension or acute coronary syndrome 9. Severe other organs dysfunction with a low expected survival (7 days) or palliative care 10. Solid organ or hematologic tumors with the expected survival time less than 30 days 11. Participating in other clinical trials within 30 days 12. Pregnancy 13. Refusal to sign the informed consent

Design outcomes

Primary

MeasureTime frameDescription
28-day mortalityat day 28mortality in Day 28

Secondary

MeasureTime frameDescription
Proportion requiring rescue therapiesday 28Proportion of people who require rescue therapies
Blood pressure at day D1, 2, 3, and 7 from enrollmentup to 24 monthsBoth systolic and diastolic pressure at day D1, 2, 3, and 7 from enrollment
respiratory rateup to 7 daysrespiratory rate
number of shock and gastrointestinal hemorrhageday 28shock, and gastrointestinal hemorrhage
VFDs at day 28at day 28defined as the number of days between successful weaning from MV and day 28 after study enrollment
Shock-free days at day 28at day 28Shock-free days at day 28
Length of ICU stayup to 24 monthsthe survival rate(survival/total) during ICU stay
Length of hospital stayup to 24 monthsthe survival rate(survival/total) during hospital stay
The rate of successful weaningat day 28Proportion of people who are not dependent on ventilator ventilation
Rate of pneumothoraxday 28Rate of pneumothorax
driving pressureday 0, day 1, day 2, day 3, day 7measurement as one index of respiratory compliance at day 0, 1, 2, 3, and 7 from enrollment
Sequential Organ Failure Assessment (SOFA) score at the time of enrollmentat the time of enrollmentSOFA range from three to eight. The higher the score, the worse the prognosis

Other

MeasureTime frameDescription
Ventilator parameters and respiratory mechanics28 dayVT, RR, PEEP, FiO2, compliance, resistance and so on
vital signs28 dayHR, MAP, RR, SPO2, CVP, CO and so on at each time point
blood gas28 dayblood gas and the change at each time point

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026